Joint Commercialization Committee. The JCC shall perform the following functions:

The JCC shall oversee Commercialization of the Licensed Product in the Field in the Territory. As soon as practicable following the Effective Date (but in no event more than thirty (30) days following the Effective Date), each Party shall designate its initial representatives on the JCC. Licensee shall appoint a person from among its representatives to serve as the chairperson of the JCC. The chairperson shall coordinate administrative activities of the JCC, but shall not have any greater authority than any other representative on the JCC. Each Party shall be free to change its representatives on notice to the other or to send a substitute representative to any JCC meeting; provided, however, that each Party shall ensure that at all times during the existence of the JCC, its representatives on the JCC are appropriate in terms of expertise and seniority (including at least one member of senior management) for the then-current stage of Commercialization of Licensed Product in the Field in the Territory and have the authority to bind such Party with respect to matters within the purview of the JCC.

Joint Commercialization Committee. At either Party’s request, the Parties shall establish a joint commercialization committee (the “Joint Commercialization Committee”) to monitor and facilitate the Commercialization of Licensed Products in the Field in the Territory and the ROW Territory, including the review and discussion of the parameters of a Global Brand Plan for the Licensed Products on an annual basis. The Parties may, in each of their sole discretions, seek to align on aspects of implementation of the Global Brand Plan in their Applicable Territory, including trademarks (names and logos), color and marketing strategy, and promotional campaigns and marketing messages based on the approved labeling of the Licensed Products in each Party’s Applicable Territory, in each case, subject to Applicable Law in each Party’s Applicable Territory.

Joint Commercialization Committee. ​ the Parties shall establish a joint commercialization committee (the “Joint Commercialization Committee” or “JCC”), which shall consist of ​ representatives from each of the Parties, each with the requisite experience and seniority to enable such person to make decisions on behalf of the Parties with respect to the issues falling within the jurisdiction of the JCC. From time to time, each Party may substitute ​ of its representatives to the JCC upon written notice to the other Party. ​ shall appoint ​ of its representatives to serve as a co-chairperson of the JCC, and ​ may change its appointed co-chairperson from time to time upon written notice ​. The JCC shall:

Joint Commercialization Committee. At a time to be determined by the JSC (but no later than the submission of the first NDA for the Product in the Territory), each Party shall appoints three (3) representatives to serve on a joint Commercialization committee (the “Joint Commercialization Committee” or the “JCC”) to oversee the Commercialization of the Product in the Field in the Territory under this Agreement. The JCC shall in particular: ​.

Joint Commercialization Committee. At a time to be determined by the JSC (but no later than the submission of the first NDA for the Product in the Territory), each Party shall appoints three (3) representatives to serve on a joint Commercialization committee (the “Joint Commercialization Committee” or the “JCC”) to oversee the Commercialization of the Product in the Field in the Territory under this Agreement. The JCC shall in particular: ​.

The JCC’s primary responsibilities shall include, but shall not be limited to, the following functions or roles:

Joint Commercialization Committee. No later than the commencement of the first Initial Trial under the Joint Development Plan, the Parties shall form a Joint Commercialization Committee (the “JCC”) to oversee global Commercialization activities and to serve as a decision-making forum. The JCC shall consist of ​. Each Party shall be responsible for determining the qualifications and substitutions of its JCC members. It is anticipated that each Party’s representatives may include experts in clinical development, global commercialization, and supply. The JCC shall be co-chaired with one chairperson designated by each Party (each, a “JCC Co-Chair”). The JCC shall meet at least ​, or at such other frequency as the JCC agrees (and it may appoint working teams to meet more frequently), provided that either Party through its JCC Co-Chair may request a meeting of the JCC at any time upon ​ notice to the other Party, with the understanding that the other Party will use reasonable efforts to comply with such request but such other Party will not be in breach of this Agreement in the event that it is unable to comply with such request but is using reasonable efforts to conduct a JCC meeting as promptly as practicable. Upon request by either Party, such meetings will be held by audio or video teleconference; provided that face-to-face meetings shall occur at least ​, alternating between Princeton, NJ and San Francisco, CA unless otherwise agreed upon by the Parties. There must be a minimum of ​ from each Party at any meeting of the JCC to constitute a quorum for decision-making. No fewer than five (5) Business Days prior to each meeting, and in any event as soon as reasonably practicable, each Party shall use good faith efforts to disclose to the other Party any proposed agenda items together with appropriate supporting information. The Alliance Managers shall alternate responsibility for preparing and circulating definitive minutes of each meeting of the JCC. Such minutes shall provide a description, in reasonable detail, of the discussions at the meeting, a list of material actions and decisions made by the JCC, a list of action items made by the JCC and a list of material issues not resolved by the JCC. The Alliance Manager who drafts the minutes shall provide the other Alliance Manager and each Party’s JCC Co-Chair with the

No later than ​ prior to the anticipated date on which the first Regulatory Approval of a SYROS Product is expected, the Parties will form a joint commercialization team (the “Joint Commercialization Committee” or “JCC”). The JCC will (as considered reasonable by each Party, in its sole discretion and to the extent legally allowed), discuss a coordinated approach for the sales and marketing of the QIAGEN IVD for use with the SYROS Product. Such JCC shall be constituted and shall operate as the JSC determines and as may be outlined in the relevant Schedule.

Joint Commercialization Committee. Unless otherwise agreed upon between the Parties, within [ * ], the Parties shall form and establish a joint commercialization committee (the “Joint Commercialization Committee” or “JCC”), composed of [ * ] of each Party that have [ * ] in the commercialization of products similar to the Collaboration Products, to monitor